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Abstract: Parkinson’s disease (PD) is a progressive neurodegenerative disorder with prominent motor 
and non-motor symptoms. Psychosis develops in over 40% of PD patients and it is one of the most dis-
tressing symptoms for patients and caregivers alike. Until recently, atypical antipsychotics, clozapine 
and quetiapine were used to treat psychotic symptoms, but treatment was associated with substantial 
concerns for side-effects of clozapine and unfounded efficacy for quetiapine. Extensive research has 
shown that the antipsychotic effect of these drugs could be attributed to serotonin 2a receptor (5-HT2a) 
triggered mechanisms. A selective 5-HT2a inverse agonist, pimavanserin, has been developed, investi-
gated and has gained approval in April 2016 in the US for the treatment of hallucinations and delusions 
in PD. In this review we primarily focus on psychosis in PD, the current treatment possibilities and the 
new, emerging therapy, pimavanserin, a selective 5-HT2a inverse agonist. All articles were reviewed in 
this topic and indexed in PubMed with keywords: Parkinson’s disease psychosis, serotonin 2a receptor 
inverse agonist, clozapine, quetiapine, pimavanserin. 
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1. INTRODUCTION 
 Parkinson’s disease (PD) is a neurodegenerative disorder 
which is characterized by motor and non-motor symptoms. 
Incidence of Parkinson’s disease is 4-20/100,000 while 
prevalence is 0.3% in industrialized countries [1]. The num-
ber of PD patients is constantly increasing, thus inducing 
more vigorous research in the field. A range of symptomatic 
treatments is available for motor symptoms, mainly targeting 
dopamin receptor activation or levodopa supplementation. 
However, effective therapy for non-motor symptoms is ea-
gerly awaited. Non-motor symptoms include depression, 
apathy, fatigue, impulse-control disorders, sleep disturbances 
and in 40-60% of patients, psychosis and dementia [2]. Psy-
chosis consists of a wide spectrum of phenomena including 
hallucinations, delusions and minor symptoms of illusions 
and sense of presence [3-5]. Visual hallucinations occur in 
20-30% of drug-treated PD patients, whereas auditory and 
tactile hallucinations are seen in 48% and 23% of the cases, 
respectively [6, 7]. Delusions are mainly characterized by 
jealousy and paranoia [8].  
 The etiology of PD psychosis is multifactorial. In the 
past, symptoms were solely accredited to side-effects of  
 
*Address correspondence to this author at the Department of Neurology, 
University of Szeged, Faculty of Medicine, Albert Szent-Györgyi Clinical 
Centre, Semmelweis u. 6., H-6725 Szeged, Hungary; Tel: +36 62 545348; 
Fax: +36 62 545597; E-mail: vecsei.laszlo@med.u-szeged.hu  
dopaminergic medication, anticholinergics and other PD 
drugs. Presently, however, it is thought, that both extrinsic 
and intrinsic factors contribute to the development of psychi-
atric symptoms in PD.  
 Antiparkinson therapy is considered the most important 
extrinsic factor together with various environmental stimuli, 
and intercurrent comorbidities. The effect of levodopa re-
placement has been emphasized, however, the cause and 
effect relationship is difficult to discern. Frequently psy-
chotic symptoms emerge during drug dose modification or 
the introduction of levodopa. On the other hand, a clear cor-
relation between psychotic symptoms and dose increase was 
not found [2, 9]. A high dose intravenous challenge did not 
precipitate hallucinations [10]. Dopamin-agonists have also 
been implicated. Data suggest that patients on dopamine-
agonist therapy might be more prone to have hallucinations 
than patients on levodopa [11]. In addition, intercurrent in-
fections and other comorbidities play a crucial part in the 
development of psychosis as extrinsic factors. They can 
cause delirium, but also trigger pathological processes, e.g.: 
through inflammation, which contribute to the underlying 
neurodegenerative pathomechanisms [12].  
 Intrinsic factors are fundamentally disease-related with 
degenerative processes involving several neurotransmitter 
systems in the brain, abnormalities of the visual system, the 
presence of cortical Lewy body pathology and brainstem 
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sleep dysfunction [13, 14]. The pathological process influences 
several aspects of the disease, which contribute greatly to the 
development of psychosis. The time of onset (early vs. late 
onset), severity and duration of the disease as well as the age 
of the patient, the subtype of PD are all determining factors 
[12].  
 It has been shown that certain psychiatric diseases can 
precede motor symptoms of PD and PD psychosis [15]. Prior 
depression and anxiety may occur with greater risk among 
PD patients and their relatives especially in early-onset PD 
[16, 17]. A genetic contribution has been suggested in the 
background, by data showing, that relatives of early-onset 
PD patients with a compound heterozygous mutation in the 
parkin gene, without signs of PD, may have a higher risk of 
depression [18]. Nonetheless, there was no correlation be-
tween early-onset PD patients with parkin mutations and 
prior depression. A study from Taiwan showed a strong cor-
relation between prior anxiety, affective disorders, schizo-
phrenia and subsequent PD [19]. As opposed to this, other 
investigators found no association between preceding bipolar 
disorders or schizophrenia and PD [20]. 
 Dementia is also closely associated with PD psychosis. 
Psychosis occurs more frequently in PD with dementia than 
without [9, 12].  
 Other studies investigated genetic causes in connection 
with PDP. From several polymorphisms studied, the -45C>T 
polymorphism of the CCK gene was found to have increased 
associations with hallucinations in PD [12, 21]. Glucocere-
brosidase mutations also showed a close correlation with the 
development of psychosis [22].  
 Considering the above, at the appearance of psychosis, 
secondary causes (e.g. infection) have to be excluded first. If 
this yields no effect, then the current PD medication should 
be reconsidered with a focus on anticholinergics, tricyclic 
antidepressants, MAOB inhibitors, amantadine, and at the 
end dopamine agonists and levodopa [23]. In case of persis-
tent and progressive symptoms, specific antipsychotic treat-
ment should be implemented. 
 Until recently clozapine and quetiapine, two atypical 
antipsychotics, have been used in the treatment of PDP. 
These drugs produce significantly less D2 receptor blockade 
than typical antipsychotics, with clozapine bearing the high-
est affinity ratio for the 5-HT2a relative to D2 receptors 
amongst atypical antipsychotics and also acting on D4 recep-
tors [24]. When introduced into the therapic regimen, they 
allow the continuation, even maximalisation of previous PD 
treatment without further worsening PD motor symptoms 
[25, 26]. However, neither medication gained approval by 
the FDA (Food and Drug Administration) because of poten-
tial serious side effects, consequential need for frequent 
blood monitoring in case of clozapine and unconfirmed effi-
cacy for quetiapine. From the two, clozapine is the drug 
which has shown efficacy and tolerability with monitorable 
safety risks in randomized clinical trials [25, 27, 28]. Addi-
tionally to controlling psychosis, clozapine has also reduced 
tremor and levodopa-induced dyskinesias. These effects, 
however, can be observed mostly at moderate or high doses, 
which are tolerated poorly [25, 29, 30]. Even with the intro-
duction of the drug at low doses (6.25-50 mg/day), there are 
several side-effects, which constitute a major drawback. 
Agranulocytosis, neutropenia can occur, independent of the 
dose, in most cases at the beginning of the treatment. There-
fore frequent blood checks are required, weekly for 6 
months, then every other week for 6 months and then once a 
month. Myocarditis, which is also considered to be a hyper-
sensitivity reaction, independent of the dose, is rare in PD. 
Sedation, orthostatic hypotension and hypersalivation are 
problems most likely resulting from H1 and alpha1 adrenore-
ceptor blockade [26, 31, 32]. The increased sedative effect of 
the drug potentiates the excessive daytime sleepiness seen in 
PD patients. Metabolic side effects (weight gain, hypergly-
caemia) and anticholinergic effects seem to have a dose-
dependent relationship and, thus, they are seldom seen in PD 
patients [26, 33]. Prolactinaemia, which is a frequent side-
effect of haloperidol and risperidone treatment, cannot be 
observed during clozapine and quetiapine therapy. The 
drugs’ combined affinity for 5-HT2a and D2 receptors achieve 
sufficient 5-HT2a receptor blockade in the hypothalamus to 
counteract the effects of D2 receptor blockade in the pituitary 
gland, which otherwise cause prolactin elevation in pure D2 
antagonists [34]. The lack of motoric side-effects is attrib-
uted to the “fast-off dissociation” of clozapine from striatal 
dopamine D2 receptors compared with other antipsychotics 
[35].  
 Consequently, after consideration of the possible, serious 
side-effects associated with clozapine, physicians often pre-
scribe quetiapine. It is generally well-tolerated, despite the 
frequent sedative, hypotensive effects and dizziness, and 
there is a clinical impression of effectiveness. Metabolic 
syndrome and anticholinergic effects are usually dose-
dependent. On the other hand, data concerning efficacy are 
controversial. Quetiapine was shown to be effective in open-
label trials in treating psychosis [36, 37]. Placebo-controlled, 
double-blind, randomized trials, however, concluded oppo-
site results, with quetiapine failing to overpower placebo in 
the therapy of PDP [38-41].  
 Age-related factors have to be taken into consideration as 
well. Data show that old-age onset PD is associated with an 
increased frequency of psychosis, dementia, sleep disorders, 
autonomic, olfactory and sensory symptoms as opposed to 
early onset PD [42]. Medication-related psychotic symptoms 
in PD also appear at a later age, when comorbidites are more 
common as well. In case of both clozapine, and quetiapine, 
however, increased mortality, morbidity and adverse events 
have been documented in elderly, demented patients, which 
present a problem in treatment. After consideration of the 
findings, a black box warning was issued for the treatment of 
behavioral disorders in elderly patients with dementia by the 
FDA, in 2005. Later studies also verified these data in a 
study on patients with various forms of dementia, published 
in 2015 [43]. Quetiapine, which consistently proved to be 
less harmful than the other AP drugs studied, still increased 
mortality by 2.0% compared to the control group. Another 
study extended investigations specifically to patients with 
PDP [44]. Results reinforced earlier observations of higher 
mortality however they showed that the increased risk is not 
specific to dementia in PDP. The various AP drugs studied 
conferred different risks, with typical antipsychotics posing 
the greatest. Authors also concluded that PD disease related 
risk factors substantially predispose patients to adverse 
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events and add to the increased risk of mortality compared to 
other dementia patients.  
 Treatment with quetiapine and clozapine in the elderly 
predisposes patients to other severe adverse events as well. 
Neuroleptic malignant syndrome (NMS) has been docu-
mented in the elder patient population, although much less 
frequently than with other antipsychotics. This is attributed 
to the different receptor affinity profile of clozapine and 
quetiapine, these medications having less antidopaminergic 
(D2) effect than other antypsychotics [45, 46]. In addition, 
both drugs can cause QT interval prolongation. It is advised 
to do ECG examination at baseline and pay increased atten-
tion to drug interactions. 
 Thus, the choice between antipsychotics is difficult. The 
boundaries of former treatments and steadily increasing 
number of patients with PDP emphasize the importance of 
the need for the development of new, safer treatments. 
2. THE IMPORTANCE Of 5-HT2a INVERSE AGO-
NISM AND THE DEVELOPMENT OF PIMAVAN-
SERIN 
 The pathomechanism behind the development of psy-
chotic symptoms and anti-psychotic therapy in Parkinson’s 
disease is complex. Several neuronal receptor families have 
been implicated. Initial observations from the antipsychotic 
treatment of patients with first generation antipsychotics 
have proposed that their antipsychotic effect might be ex-
erted through the blockade of limbic D2 dopamine receptors. 
Further drug development has led to the introduction of 
atypical antipsychotics with better efficacy and side-effect 
profile. The evaluation of the affinities of typical and atypi-
cal antipsychotic medication for dopamine receptor D1, D2 
and 5-HT2a receptors, in the light of their antipsychotic ef-
fect, resulted in the hypothesis, that a more likely basis for 
antipsychotic activity is the blockade of 5-HT2a receptors 
[47, 48]. 
 This theory is advocated by facts from both animal ex-
periments and human studies of 5-HT2a receptors. Hallucina-
tions can be provoked by the stimulation of cortical 5-HT2a 
receptors and can be abolished by selective 5-HT2a inverse 
agonists and antagonists [49]. Hallucinogenic compounds, 
e.g. lysergic acid diethylamide, psilocybin and mescaline 
display high affinity for 5-HT2A receptors and the pharma-
cological or genetic inactivation of 5-HT2A receptors inhibit 
the behavioral effects of hallucinogens in various species, 
including mice, rats and humans [50]. However, it is difficult 
to investigate hallucinations in animals. Behavioral animal 
models cannot exactly capture the disturbances of perception 
and cognition elicited by hallucinogens and it is currently 
uncertain if animals actually hallucinate and to what degree, 
since hallucinations are subjective experience that require 
self-report. Therefore, in animal studies a variety of specific 
responses are examined, such as changes in exploratory be-
havior, grooming, interruption of operant responding, head 
twitch response, etc. [50]. 
 In schizophrenia patients, initial PET studies with clozap-
ine and quetiapine attributed the antipsychotic effect of these 
medications to the preferential occupancy of D1 and D2 re-
ceptors [51, 52], PET studies performed later, on the other 
hand, demonstrated, that visual hallucinations in PD corre-
late with excessive 5-HT2a neurotransmission [53]. PDP pa-
tients’ neocortex at autopsy has also revealed increased  
5-HT1a, 5-HT2a receptor density [54], and post-mortem 
analysis showed abnormalities of 5-HT2a receptors with in-
creased serotonin binding in the inferior temporal cortex of 
PD patients with previously observed visual hallucinations 
[55]. In addition, two studies concluded that ondansetron, a 
5-HT3 receptor antagonist alleviated symptoms of psychosis 
in PD and schizophrenia patients [56, 57]. All of these data 
suggest that a drug with selective 5-HT2a inverse agonist 
properties might prove to be useful in the antipsychotic 
regimen either as an adjunctive treatment or a monotherapy. 
Several compounds were created, mainly by ACADIA 
Pharmaceuticals. The compound fitting the criteria was 
ACP-103 or pimavanserin [58]. Its pKi (-log Ki) for the hu-
man 5-HT2a receptor is 9.3, having a 40-fold selectivity over 
the 5-HT2c receptor and lacking affinity for the 5-HT2b or D2 
receptors [58]. As opposed to clozapine and quetiapine, pi-
mavanserin does not influence H1 and alpha1 adrenoceptors 
which are responsible for sedative and hypotensive effects 
[31]. On the whole, pimavanserin is a compound, acting 
primarily on serotonin receptors, which are uniquely impli-
cated in the pathogenesis of PDP, without the side-effect 
profile of the previously used antipsychotics. 
3. PIMAVANSERIN AS A NOVEL THERAPY FOR 
PDP 
 The structural characteristics of pimavanserin are very dif-
ferent from other APDs. The chemical formula of pimavanserin 
is (1-[(4-fluorophenyl) methyl]-1)1-methylpiperidin-4-yl)-3-




Fig. (1). Chemical structure of antipsychotic drugs. 
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 Previously, in preclinical studies it has been identified as 
ACP-103. The clinically tested compound contains pimavan-
serin and tartrate in a 2:1 ratio, the molecular weight is 
1005.12g/mol.  
 Pimavanserin is a highly selective inverse agonist of the 
5-HT2a receptor, it displaced the binding of [3H] ketanserin 
to 5-HT2A receptors in both membranes and whole cells with 
mean pKi values of 9.30 and 9.70 in membranes and whole 
cells, respectively. The drug‘s potency and efficacy as  
5-HT2a receptor inverse agonist was determined using the 
cell-based functional assay R-SAT (Receptor Selection and 
Amplification TechnologyTM) with a mean pIC50 of 8.73 and 
93% inhibition.  
 Pimavanserin is also a ligand for 5-HT2c receptors, but 
with a much lower affinity (mean pKi 8.80 in membranes 
and 8.00 in whole cells, as determined by radioligand bind-
ing), and it’s potency as an inverse agonist for 5-HT2c recep-
tors was determined with a mean pIC50 of 7.04, and 110% 
inhibition in R-SATTM. Experimental data also indicated, 
that it has no effect on the 5-HT2b receptors, the dopamine 
D2 receptor or any other G-protein coupled receptors [58].  
 In addition, pimavanserin was able to attenuate character-
istic behavioral changes in rats, e.g. head-twitches and  
prepulse inhibition induced by (±)-2,5-dimethoxy-4-
iodoamphetamine hydrochloride. It also reduced hyperactiv-
ity induced by an N-methyl-D-aspartate receptor antagonist 
[58]. 
 The pharmacokinetic parameters of pimavanserin have 
been established in healthy young male volunteers. The 
compound was evaluated after both single and multiple oral 
doses in two single-center, randomized, double-blind, pla-
cebo-controlled, escalating dose studies [59]. In the first 
study, pimavanserin was administered in single doses rang-
ing from 20 to 300 mg/day with equal doses of placebo, 
whereas in the second study, subjects took 50, 100 or 150 
mg fixed daily dose of pimavanserin for 14 days, with con-
trol subjects receiving a single daily dose. The serum half-
life of pimavanserin was around 55-57h, with a Tmax being at 
6h. These values were independent from the administered 
doses. The analysis revealed that pimavanserin is highly pro-
tein-bound (more than 91%) [59]. The inter-subject variabil-
ity of the parameters was low. Data referred to the oral solu-
tion of the compound, which was administered either in the 
form of a solution directly, through a nasogastric tube or in 
the larger doses, in plastic capsules. However, later an im-
mediate-release, coated tablet was formulated [60]. The oral 
solution and the coated tablet displayed similar pharmacoki-
netic parameters, maximum plasma concentrations and simi-
lar tmaxvalues, consequently, the two formulations were con-
sidered bioequivalent [61]. In the same study the effect of 
food intake was also assessed, the results indicated, that it 
did not alter the absorption or other pharmacokinetic pa-
rameters of pimavanserin [61]. 
 No serious adverse events could be detected in the first 
study. The most common, mild, adverse event was postural 
dizziness observed after taking higher doses of pimavan-
serin. There were two subjects, receiving 200 and 300 mg 
dose respectively who experienced vasovagal episodes with 
bradycardia and a 2 to 8 and 2.9 second pause, which then 
returned to normal values. These alterations were not consid-
ered clinically significant [59]. In the second study there 
were again no severe adverse events. Mild tremors, nausea 
and vomiting were reported. One subject, who received 150 
mg dose of pimavanserin, experienced a vasovagal episode 
with an approximately 15 second pause, which later returned 
to normal and was not considered clinically relevant. One 
subject, who received a 100 mg dose, met outlier criteria for 
PR and QRS intervals intermittently, which were absent at 
baseline. Additionally, there were seven subjects who met 
outlier criteria for QT intervals at least one time. Readings 
showed QT intervals greater than 430 ms, which were absent 
at baseline. 
 After promising preclinical results, the first clinical study 
aimed to assess the safety and tolerability of the drug in pa-
tients with PDP. This initial, double-blind, placebo-
controlled study involved only 12 patients, who received 
placebo, 25 mg, and 100 mg of pimavanserin, respectively, 
for 14 days. Results indicated safety and tolerability [62]. 
There followed a phase II double-blind study, which re-
cruited 60 PD patients with hallucinations and delusions. The 
aim of the study was again the evaluation of tolerability and 
safety, but with an initial outlook on whether the drug is able 
to attenuate psychotic symptoms. Antiparkinsonian therapy 
was stable during the study. Patients were randomly assigned 
to placebo or 20 mg of pimavanserin, with the possibility of 
dose increase to 40 or 60 mg during the study, according to 
patients’ needs. At the closure of the study, pimavanserin 
dose escalated to 44.8 mg, whereas the equivalent, placebo 
dose was 55.9 mg. This study confirmed that the side-effects 
did not differ significantly from placebo and pimavanserin 
did not worsen motor symptoms. Moreover, a good effect 
could be detected on the scale for assessment of positive 
symptoms (SAPS) hallucinations and delusions domains and 
significant attenuation of psychosis on the global item rat-
ings of hallucinations and delusions [62]. On the other hand, 
no significant difference could be seen in the primary out-
come measure of the SAPS total domain score for delusions 
and hallucinations. No severe adverse event was recorded 
related to the study. Syncope with bradycardia did not occur. 
The milder adverse events detected were edema, somnolence 
and elevation in blood urea nitrogen. One patient dropped 
out of the study because of worsening hallucinations. 
 After the promising results of the phase II trial, a larger 
international PDP study was conducted (ACP-103-012), 
which involved 298 PDP patients who received either pla-
cebo, 10 mg or 40 mg pimavanserin once a day for 6 weeks. 
Although there were signs of effectiveness, this did not reach 
statistical significance on the SAPS hallucinations and delu-
sions scale. The result was accredited to an unexpectedly 
large placebo response [62]. Another international trial 
(ACP-103-014) was also launched, enrolling only 123 PDP 
patients, but was stopped early after the results of the previ-
ous (ACP-103-012) were becoming obvious. From the three 
arm (placebo, 10 and 20 mg pimavanserin) study, the 20 mg 
group seemed to show effectiveness without statistical sig-
nificance on SAPS hallucination+delusion scale.  
 After some methodological changes, a Phase III trial 
(ACP-103-020) was initiated, which later showed efficacy of 
pimavanserin 34 mg/day (administered as pimavanserin  
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tartarate 40/mg) in all evaluated endpoints. This study in-
volved PD patients with moderate to severe psychosis symp-
toms assessed by trained, independent raters on video. Item 
number was decreased from 20 items to 9 on the SAPS scale 
to better fit PDP patients, leaving out those, which were 
more suitable for schizophrenia. The new scale was called 
PD-adapted Scale for Assessment of Positive Symptoms 
(SAPS-PD) [63]. A two-week psychosocial therapy was 
given before the beginning of the study. Inclusion criteria 
was defined as a minimal combined score of 6 on the Neuro-
psychiatric Inventory or a minimal score of 4 on the individ-
ual sections on hallucinations or delusions, and a minimal 
score of 3 on SAPS-PD. Pimavanserin effectively reduced 
psychotic symptoms assessed SAPS-PD. A 37% reduction 
was found compared to a 14% reduction achieved by the 
placebo. Improvement was also seen according to the physi-
cian’s clinical global impression (clinical global impression 
severity and improvement scores). Pimavanserin improved 
sleep quality and daytime wakefullness as well. [64-67]. It is 
also important to note, that subject age, gender or MMSE 
score did not influence the results, pimavanserin seemed 
effective regardless of these variables. Motor symptoms did 
not worsen. There were 10 withdrawals in the pimavanserin 
group as opposed to 2 in the placebo. Psychosis symptoms 
accounted for six withdrawals, four due to psychotic disorder 
or hallucination within 10 days of start of the study drug. 
There were 2 deaths due to sepsis in the pimavanserin group 
and one sudden cardiac death occurred in the control group, 
however the deaths were not considered study related. A QT 
interval increase could be detected in the pimavanserin group 
without additional clinical consequences [64]. 
 The patients participating in the Phase II (ACP-103-006) 
and Phase III (ACP-103-012, -014, -020) studies were en-
rolled in further open-label extension studies. Patients who 
have been receiving the drug were allowed to continue, 
while those on placebo had the possibility to switch to pi-
mavanserin. Previous phase II patients were followed by the 
clinical global impression severity scale, whereas the phase 
III patients were followed by the SAPS and clinical global 
impression scales. The phase III extension study is still on-
going, interim analysis results confirmed long-term safety 
and efficacy of pimavanserin [66-69]. SAPS-PD scores 
showed improvement in case of patients previously on pla-
cebo. In case of patients receiving pimavanserin earlier, sta-
bilization of the beneficial effect could be observed, without 
any serious adverse events. Discontinuation for lack of effec-
tiveness was less than 20% [66, 68]. 
 Another open-label safety extension study examined pi-
mavanserin combined with add-on antipsychotics. Results 
showed, that in the case of combination of pimvanserin with 
other antipsychotics, the rate of mortality, adverse events and 
worsening of parkinsonian symptoms was significantly 
higher compared to the patients receiving pimavanserin 
alone [66]. The age, gender, disease parameters and cogni-
tive status was harmonized between the two groups. 
 To investigate possible application of pimavanserin in 
other diseases with pscyhosis, phase II studies were initiated 
in schizophrenia and Alzheimer’s disease. The study in pa-
tients with Alzheimer’s disease is still ongoing, however the 
phase II study of pimavanserin (ACP-103-008) added on to 
sub-optimal dosage of other antipsychotic drugs had been 
completed [70]. 20 mg of pimavanserin given daily in addi-
tion to risperidone in a sub-optimal dosage (1 mg twice 
daily) resulted in faster effect, equivalent efficacy and better 
safety than monotherapy with risperidone only [70]. In con-
trast, the addition of the same dose of pimavanserin to a sub-
optimal dose of haloperidol (2 mg/day) was not more effec-
tive than the same dose haloperidol plus placebo [70]. 
3.1. Adverse Events 
 The assessment of adverse events is mainly based on the 
experience gained through the phase III, placebo-controlled 
trial and the open-label safety extension trials, which evalu-
ated once-daily pimavanserin dose of 34 mg compared  
to placebo (data available from http://www.acadia-
pharm.com/wp-content/uploads/2016/04/Nuplazid-
pimavanserin-Package-Insert.pdf).  
 The most common adverse events, where incidence was 
≥5% and at least twice the rate of placebo, were peripheral 
edema (7% pimavanserin 34 mg vs 2% placebo) and confu-
sional state (6% pimavanserin vs 3% placebo). Other adverse 
reactions which led to discontinuation of treatment were hal-
lucination (2% pimavanserin vs <1% placebo), urinary tract 
infection (1% pimavanserin vs <1%placebo) fatigue (1% 
pimavanserin vs 0% placebo), constipation (4% pimavan-
serin vs 3% placebo) and gait disturbance (2% pimavanserin 
vs <1% placebo). (data available from http://www.acadia-
pharm.com/wp-content/uploads/2016/04/Nuplazid-
pimavanserin-Package-Insert.pdf).  
 There were no detected differences between population 
subgroups in safety on the basis of age or sex. Ethnic differ-
ences could not be discerned because the patient population 
was predominantly Caucasian. 
 Pimavanserin has the potential to prolong the QT inter-
val, thus it is contraindicated in patients with known QT pro-
longation and it should not be administered with drugs that 
are known to prolong the QT interval (data available from 
http://www.acadia-pharm.com/wp-content/uploads/2016/04/ 
Nuplazid-pimavanserin-Package-Insert.pdf).  
 A dosage reduction to 17 mg is advised when pimavan-
serin is administered with strong CYP3A4 inhibitors, 
whereas if it is used with a CYP3A4 inducer, an increase in 
dosage might be recommended. Adjustment of pimavanserin 
dosage is not needed when administered together with 
levodopa, according to drug interaction studies. (Data avail-
able from http://www.acadia-pharm.com/wp-content/uploads/ 
2016/04/Nuplazid-pimavanserin-Package-Insert.pdf). However, 
pimavanserin is not recommended in patients with severe 
renal or hepatic impairment. Pimavanserin has a black box 
warning of increased mortality in elderly patients with de-
mentia-related psychosis and the drug is not approved for 
dementia-related psychosis symptoms unrelated to the psy-
chotic symptoms of PDP. Treatment with atypical antipsy-
chotics increased the risk of death significantly in 17  
analysed trials (data available from http://www.acadia-
pharm.com/wp-content/uploads/2016/04/Nuplazid-
pimavanserin-Package-Insert.pdf).  
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4. DISCUSSION 
 Several neurotransmitter systems have been implicated in 
the pathogenesis of Parkinson’s disease. Although dopa-
minergic deficit is considered the hallmark of the disease, 
substantial contribution of serotonergic, cholinergic and glu-
tamatergic dysfunction has also been recognized. Serotoner-
gic neurons of the raphe nucleus are affected early in the 
course of the disease with gradual deterioration of serotoner-
gic projections to the striatum, frontal and temporal lobes 
[71]. Consistent with the Braak staging, Lewy body deposi-
tion of the caudal brainstem raphe nuclei is observed in 
Braak stage two, previous to that seen in midbrain dopa-
minergic neurons [72]. PET studies on early, established and 
advanced PD patients have shown that there is a nonlinear 
reduction of 5-HT receptor activity throughout the course of 
the disease which is not related to disease duration, motor 
function or dopamine replacement therapy. Serotonergic 
neurons are involved differently from dopaminergic neurons, 
with neurons affected more in the caudate than in the pu-
tamen [72]. The reduction of serotonergic neurons can likely 
cause a compensatory upregulation of post-synaptic 5HT2A 
receptors which results in an imbalance in the function of 
these receptors. The dysregulated dopamine release from 
remainding serotonergic reminals in the form of a „false neu-
rotransmitter”, after dopamine replacement therapy, can also 
contribute to the hypersensitivity of serotonin receptors [73]. 
At the end, overstimulation of 5HT2A receptors leads to hal-
lucinations in PD [53, 55]. 
 In light of these pathomechanisms the rationale for the 
development of 5HT2A receptor influencing drugs is well 
substantiated. 
 Pimavanserin, through its selective inverse agonistic ef-
fect on 5-HT2a receptors, is the first drug approved by the 
FDA for the treatment of hallucinations and delusions asso-
ciated with Parkinson’s disease [67]. The completed phase II 
and phase III studies as well as the interim analysis of the 
ongoing open label extension studies showed good tolerabil-
ity, safety and efficacy in the treatment of PDP. A meta-
analysis of all the studies by Yasue et al. reported that pi-
mavanserin was associated with less orthostatic hypotension 
than placebo and there were no significant differences in 
rates of all-cause discontinuation, adverse events, and death, 
UPDRS-II+III scores, and incidences of individual adverse 
events (other than orthostatic hypotension) between pi-
mavanserin and placebo groups. No negative modulator was 
found for the 5-HT2A receptor [74]. Overall, data are very 
promising. Pimavanserin has shown no negative impact on 
motor symptoms of patients and it also lacks the possible 
serious side-effects of the previously used medications. The 
side effect profile is mild with only two: peripheral edema 
and confusion having the incidence rate of more than 5% and 
twice as the rate of placebo. The rest of the adverse reactions 
(hallucination, urinary tract infection, constipation, gait dis-
turbance, fatigue), which led to the discontinuation of treat-
ment during the studies, occur only with the incidence rate of 
less than 5%. Pimavanserin can prolong the QT interval, thus 
baseline ECG is needed and possible drug-interactions have 
to be monitored. However this is also the case with clozapine 
and quetiapine as well. It is also important to note, that dur-
ing the phase II testing of the drug, at higher doses (four to 
seven times the dose recommended), vasaovagal episodes 
were reported. Thus, a dose increase should be ruled out, 
especially in the older population, even if the patient is not 
responding as well and the physician would likely think of 
dose escalation.  
 Until now, only interim analyses have been available for 
the open-label extension studies. These data will be impor-
tant in the longrun for the identification of possible late side-
effects. Strict post-marketing monitoring is needed to further 
ensure safety with long-time use. As in the case of agranulo-
cytosis caused by clozapine, possible rare side effects can be 
recognised only with the drug tried on a larger population.  
 A very important characteristic of the drug, that must 
also be emphasized, is that no differences could be detected 
between population subgroups in safety on the basis of age 
or sex. A good safety profile was determined for older pa-
tient populations with PDP without dementia. However, if 
other antipsychotics were added on to pimavanserin, the risk 
of mortality, adverse events increased significantly, with 
worsening of other Parkinsonian symptoms. This led to the 
black box warning for treatment with pimavanserin in de-
mentia related psychosis. The above mentioned observations 
are also crucial when treating non- or slowly responding 
patients. Frequently, for them, extra measures are needed and 
the long half life of pimavanserin contributes to the dilemma. 
In case of patients who need rapid treatment for fulminant 
psychotic symptoms, there might not be enough time to 
reach pimavanserin steady state. Combination therapy with 
other antipsychotics may be necessary at the initiation of 
treatment. Protocols for these situations must be determined 
in the future. 
 In the phase II studies, PD patients with a spectrum of 
disease subtypes and severities were randomized, whereas in 
the phase III study, after refinement of the protocol, only 
moderately and severely psychotic patients were included. 
There were no exclusion criteria for certain kinds of PD 
medications. Patients could be treated with all of the drugs 
on the therapeutic palette. This means that throughout the 
studies drug interactions could be evaluated between pi-
mavanserin and other PD therapy. The conclusion was that 
no interaction could be observed between pimavanserin and 
levodopa, dopamine agonist or other PD medication, which 
will help the addition of pimavanserin to other PD therapies 
in all types of patients.  
 Pimavanserin’s good tolerability and safety profile will 
most certainly advance the introduction of the “antipsychotic 
drug” in the therapeutic scheme. While clozapine and queti-
apine were introduced usually after serious consideration, 
only when psychotic symptoms were devastating, this new 
drug, developed with the specific intention of PDP treatment, 
could be used at the first appearance of psychotic alterations, 
making everyday life more acceptable for the patient and 
decreasing caretaker burden. The number of PD and PDP 
patients is increasing world-wide, and an antipsychotic drug, 
which is easy-to-use, might even facilitate clinicians to 
evaluate patients more precisely for early signs of psychosis 
in PD. As a recent report has shown minor hallucinations can 
occur in drug-naive PD patients even in the premotor phase 
[75]. 
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 There are other potential uses of pimavanserin. Data from 
the Phase III study showed that the sleep quality of the pa-
tients improved and a good effect could be observed in day-
time wakefullness as well [64, 65]. Earlier studies have also 
suggested that 5-HT2A receptor antagonists and pimavanserin 
enhance slow-wave sleep [76]. This effect might later have 
therapeutic consequences as well. 
 The specific treatment of psychotic symptoms in various 
types of dementia constitutes a major demand. Medication of 
elderly, demented patients is extremely difficult. The use of 
both typical and atypical antipsychotic drugs increases the 
mortality and morbidity and comorbidities add to the thera-
peutic risk. Pimavanserin with a better side-effect profile 
might rapidly outplace other medications. A study with Alz-
heimer’s disease patients has been initiated and is still ongo-
ing. However, the treatment of psychotic symptoms in dif-
fuse Lewy body disease and Huntington’s disease would also 
be warranted. 
 Studies in the treatment of schizophrenia with pimavan-
serin have been launched. Pimavanserin enhanced the effect 
of sub-optimal dose of risperidone with equal efficacy and 
better safety than risperidone monotherapy. As an augmenta-
tion drug to haloperidol, however, the same result could not 
be achieved [70]. The reason behind the ineffectivity was 
suspected to be the dosage of haloperidol being significantly 
below the neuroleptic threshold. Dosage adjustment of 
haloperidol might lead to better results in combination with 
pimavanserin. 
 A frequent non-motor symptom of PD is depression. Se-
rotonergic involvement in the development of depression is 
supported by the observations that tryptophan depletion can 
result in depression and that symptoms react well to selec-
tive-serotonin reuptake inhibitors [77]. Chronic levodopa 
treatment might result in PD depression through serotonin 
depletion because of the competition for storage in seroton-
ergic vesicles during the conversion of levodopa into dopa-
mine [78]. Data also show, that a decrease can be detected in 
the cerebrospinal fluid levels of 5- hydroxyindoleacetic acid, 
a main metabolite of serotonin, in PD patients with depres-
sion compared to those without [79].  
 On the whole, studies suggest, that in PD depression, the 
decrease of extracellular serotonin concentration is enhanced 
through serotonin clearance by the serotonin transporter. The 
level of serotonin is further decreased by the deterioration of 
serotonergic neurons in the raphe nuclei and limbic regions. 
Additionally, a disproportionate upregulation of 5-HT recep-
tors parallels these processes. These pathomechanisms could 
be influenced by agents which hinder these processes, possi-
bly acting on serotonin transporters or on serotonin receptors 
[72]. The potential part of pimavanserin in PD depression 
has not been investigated. 
 The role of serotonin has been emphasized in connection 
with other PD non-motor symptoms as well, like fatigue, 
weight loss and obsessive-compulsive disorder. However 
further reasearch is needed to characterize the precise com-
ponent of the pathomechanisms which could be addressed by 
novel medication. The effect of pimavanserin has not been 
evaluated in these aspects. 
 Serotonin receptors have also been implicated in PD mo-
tor symptoms. Initially it was clozapine, which showed a 
significant effect in influencing levodopa-induced-dykinesias 
(LID) and tremor [29, 30]. Later, however, 5-HT receptor-
mediated mechanisms were suspected in the background. An 
animal study reported that pimavanserin reduced tremor in a 
rat model and levodopa-induced dyskinesias in a monkey 
model, however this has not been confirmed in human stud-
ies [80]. On the other hand, recent data indicated that striatal 
serotonergic terminals contribute to LIDs pathophysiology 
via aberrant processing of exogenous levodopa and release 
dopamine as a false neuro-transmitter in the denervated stria-
tum of PD patients with LIDs. The use of selective serotonin 
receptor type 1A agonists, rather than 5-HT2A inverse ago-
nists, were suggested as antidyskinetic agents in PD [25].  
 On the whole, pimavanserin offers a wide spectrum of 
treatment possibilities and it’s approval is a critical step in 
the treatment of psychosis in Parkinson‘s disease patients. It 
represents a precise approach to influencing a specific dis-
ease symptom. It’s efficacy, safety and tolerability can be-
come a useful tool in the antipsychotic regimen in PDP and 
possibly in other neuropsychiatric illnesses.  
CONCLUSION  
 The pharmacological management of PDP has not been 
resolved in the past few years. The most frequently used 
medications have been clozapine and quetiapine, whose use 
in the therapeutic regimen have been associated with various 
side-effects. Pimavanserin is a selective 5-HT2a receptor in-
verse agonist with a good oral bioavailability. Clinical trials 
have confirmed its efficacy to improve PDP with excellent 
tolerability, safety and a benign effect on motor function. 
Table 1. Summary of antipsychotic drugs to treat PDP. 
Drug name Dose Possible side-effects Monitoring needs 
Clozapine 6.25-50 mg/day 
Sedation, orthostatic hypotension, hypersalivation, 
agranulocytosis, neutropenia, NMS 
Compulsory blood monitoring during treatment for 
agranulocytosis, neutrophil and white blood cell count, 
baseline ECG for QT prolongation 
Quetiapine 50-150 mg/day 
Sedation, orthosthatic hypotension, headache,  
dizziness, NMS 
Baseline ECG for QT prolongation 
Pimavanserin 34 mg/day 
Peripheral edema, confusion, hallucination, urinary tract 
infection, fatigue, constipation, gait disturbance, 
Baseline ECG for QT prolongation 
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Pimavanserin has gained FDA approval in April 2016. It is 
therefore likely that it can become a valuable drug in the 
future for the treatment of PDP.  
LIST OF ABBREVIATIONS 
APD = Atypical Antipsychotics 
FDA = Food and Drug Administration 
LID = Levodopa-Induced-Dykinesias  
NMS = Neuroleptic Malignant Syndrome 
PD = Parkinson’s Disease 
PDP = Parkinson’s Disease Psychosis 
R-SATTM = Receptor Selection and Amplification Tech-
nologyTM 
SAPS = Scale for Assessment of Positive Symptoms  
SAPS-PD = PD-Adapted Scale for Assessment of Posi-
tive Symptoms 
5-HT2a = Serotonin 2a Receptor  
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